FDA Panel Votes on New Combination Therapy for Asthma
The vote was mixed when the data was reviewed for younger patients.
Diagnosis & Disease Information
Ensifentrine Improves Lung Function, Cuts COPD Exacerbations in Late Stage Trial
Ensifentrine (RPL554) is a first-in-class, dual phosphodiesterase (PDE) 3 and 4 inhibitor with combined bronchodilator and anti-inflammatory actions.
Dupixent Asthma Indication Expanded to Include Younger Patients
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 VOYAGE trial.
Albuterol/Budesonide Fixed-Dose Combo Looks Promising in Asthma Trials
The combination therapy significantly reduced the risk of severe exacerbations and improved lung function.
Tezepelumab Gets Priority Review for Severe Asthma
The BLA submission included data from the pivotal phase 3 NAVIGATOR trial that assessed tezepelumab in 1061 patients with severe, uncontrolled asthma.
Anaphylaxis Risk Compared for Monoclonal Antibodies Used for Severe Asthma
Data mining resulted in 2006 reports of anaphylaxis related to the use of 5 mAbs.
Tezepelumab BLA Submitted for Severe Asthma
The BLA submission is supported by data from the PATHFINDER clinical program.
- Loading...
Loading...
Next post in News
Loading... 
Loading...